NCT03744273

Brief Summary

In this prospective study, breast capsule biopsy was performed in patients undergoing 2-stage expander-implant breast reconstruction to determine its use. Prospective clinical trial was designed for 10 consecutive patients as a pilot study and approved by IRB of Samsung Medical Center. From November 2013 to May 2015, full-thickness capsule biopsy specimen was obtained from acellular dermal matrix (ADM) capsule and from native subpectoral capsule (internal control) during expander-implant exchange. Biopsy specimens were scored for fibrosis and inflammatory reactions. This is completed study and its specific title, study objective, method, and results will be available online after scientific journal submission.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 2013

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 3, 2013

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 26, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2015

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

November 14, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 16, 2018

Completed
Last Updated

November 19, 2018

Status Verified

November 1, 2018

Enrollment Period

1.6 years

First QC Date

November 14, 2018

Last Update Submit

November 15, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • histology scoring

    semiquantitative histopathologic score system of biopsy specimens (reference: Basu et al., Plastic and Reconstructive Surgery, 126: 1842, 2010)

    immediate after biopsy

Interventions

Eligibility Criteria

Age20 Years - 70 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age between 20 and 70
  • planning 2-stage expander-implant breast reconstruction using acellular dermal matrix
  • with no medical history such as diabetes, hypertension, or smoking
  • no surgical history

You may not qualify if:

  • pregnant
  • newly detected medical or surgical condition
  • acellular dermal matrix loss due to allergic reaction or prosthetic infection
  • breast cancer recurrence
  • transfer to other institution
  • reconstruction give-up due to patient's wish
  • no biopsy score

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 06351, South Korea

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Biopsy

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Jai-Kyong Pyon, MD,PhD

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Principal Investigator

Study Record Dates

First Submitted

November 14, 2018

First Posted

November 16, 2018

Study Start

November 3, 2013

Primary Completion

May 26, 2015

Study Completion

May 26, 2015

Last Updated

November 19, 2018

Record last verified: 2018-11

Locations